As the proportion of clinically site-specific ADCs increases, the abundance of novel conjugation technologies diversifies, and the linker chemistry toolkit is expanded, investments in linker and conjugation technologies have become the single-biggest area of investment for ADC drug developers.
The inaugural ADC Linker and Conjugation Summit will provide an in-depth focus on all things linker and conjugation chemistry, allowing all the chemists and bioconjugation experts working in the ADC field to be a part of important conversations surrounding the challenges facing linker and conjugation development.
Uniting 80+ pioneers with the likes of Seagen, Genentech, Bolt Biotherapeutics, and many more, this meeting will showcase brand new technologies and approaches to improve existing technologies to increase stability, avoid aggregation, and control payload release; as well as process development and manufacturing challenges centering around developing a robust process that enables a high-quality product to be produced at scale.
We hope you can join us in Boston and get empowered to analyze the right choice of linker and type of conjugation technology to be employed to develop a suite of homogenous ADCs that can provide a real-life benefit to patients, with improved efficacy and lower toxicity.
Time: 9:00 am - 3:05 pm
Drug Developer Pricing | Conference + Pre Conference Workshop Day: USD 4297.00,
Drug Developer Pricing | Conference Only: USD 2999.00,
Academic Pricing | Conference + Pre Conference Workshop Day: USD 3697.00,
Academic Pricing | Conference Only: USD 2599.00,
Service Provider Pricing | Conference + Pre Conference Workshop Day: USD 5297.00,
Service Provider Pricing | Conference Only: USD 3799.00
Speakers: Abbas El Sahili | CEO | Singzyme, BinQing Wei | Senior Scientist | Genentech Inc, Donglu Zhang | Senior Fellow - Drug Metabolism and Pharmacokinetics | Genentech Inc, Jarrod Longcor | Chief Operating Officer | Cellectar Biosciences Inc., Marc-Andre Kasper | Director, Chemistry and Early Discovery | Tubulis, Melanie Glossop | Director | Apollo Therapeutics, Mikko Myllymaki | Senior Scientist | Orion Pharma, Nathan Tumey | Assistant Professor | Binghampton University, Ning Zou | Associate Director R and D Chemistry | Regeneron Pharmaceuticals Inc, Noah Bindman | Principal Scientist | Seagen, Olivier Marcq | Vice President - CMC | Tubulis, Patrick Higgs | Principal Scientist | Iksuda Therapeutics, Paul Sauter | Director, Chemistry | VERAXA Biotech GmbH, Paul Song | Chief Scientific Officer | Genequantum Healthcare, Romas Kudirka | Director of Chemistry and Bioconjugation | Bolt Biotherapeutics, Sayumi Yamazoe | Senior Principal Scientist | Bristol Myers Squibb, Summer Ha | Postdoctoral Research Fellow | University of Texas